17p deletion in acute myeloid leukemia and myelodysplastic syndrome.: Analysis of breakpoints and deleted segments by fluorescence in situ

被引:108
作者
Soenen, V
Preudhomme, C
Roumier, C
Daudignon, A
Laï, JL
Fenaux, P
机构
[1] CHU Lille, Serv Malad Sang, F-59037 Lille, France
[2] CHU Lille, Hematol Lab, Cytogenet Serv, F-59037 Lille, France
[3] Inst Rech Canc, INSERM, U124, Lille, France
关键词
D O I
10.1182/blood.V91.3.1008.1008_1008_1015
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Recently, we and other groups reported in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) a strong correlation between cytogenetic rearrangements leading to 17p deletion, a typical form of dysgranulopoiesis combining pseudo-Pelger-Huet hypolobulation and small vacuoles in neutrophils, and p53 mutation. To gain further insight into this "17p-syndrome," we studied 17 cases of AML and MDS with 17p deletion by whole chromosome painting (WCP) and fluorescence in situ hybridization (FISH) with probes spanning the 17p arm, including a p53 gene probe. Cytogenetically, 15 patients had unbalanced translocation between chromosome 17 and another chromosome (chromosome 5 in nine cases and unidentified chromosome -add 17p-in three cases), one patient had monosomy 17, and one had i(17q). All rearrangements appeared to result in 17p deletion. Sixteen patients had additional cytogenetic rearrangements. WCP analysis confirmed the cytogenetic interpretation in all cases and identified one of the cases of add 17p as a t(17;22). WCP also identified chromosome 17 material on a marker or ring chromosome in two cases of t(5;17). FISH analysis with 17p markers made in 16 cases showed no deletion of the 17p markers studied in the last two patients, who had no typical dysgranulopoiesis; p53 mutation analysis in one of them was negative. In the 14 other cases, FISH showed a 17p deletion of variable extent but that always included deletion of the p53 gene. All 14 patients had typical dysgranulopoiesis, and all but one had p53 mutation and/or overexpression. These findings reinforce the morphologic, cytogenetic, and molecular correlation found in the 17p-syndrome and suggest a pathogenetic role for inactivation of tumor suppressor gene(s) located in 17p, especially the p53 gene. (C) 1998 by The American Society of Hematology.
引用
收藏
页码:1008 / 1015
页数:8
相关论文
共 30 条
[1]   THE SPECTRUM OF MOLECULAR ALTERATIONS IN THE EVOLUTION OF CHRONIC MYELOCYTIC-LEUKEMIA [J].
AHUJA, H ;
BARELI, M ;
ARLIN, Z ;
ADVANI, S ;
ALLEN, SL ;
GOLDMAN, J ;
SNYDER, D ;
FOTI, A ;
CLINE, M .
JOURNAL OF CLINICAL INVESTIGATION, 1991, 87 (06) :2042-2047
[2]  
BAER MR, 1990, LEUKEMIA, V4, P297
[3]   PROPOSALS FOR THE CLASSIFICATION OF THE MYELODYSPLASTIC SYNDROMES [J].
BENNETT, JM ;
CATOVSKY, D ;
DANIEL, MT ;
FLANDRIN, G ;
GALTON, DAG ;
GRALNICK, HR ;
SULTAN, C .
BRITISH JOURNAL OF HAEMATOLOGY, 1982, 51 (02) :189-199
[4]   A 3.1-Mb YAC contig within the Werner syndrome region, on the short arm of human chromosome 8 [J].
Chaffanet, M ;
Imbert, A ;
Adelaide, J ;
LePaslier, D ;
Wagner, MJ ;
Wells, DE ;
Birnbaum, D ;
Pebusque, MJ .
CYTOGENETICS AND CELL GENETICS, 1996, 72 (01) :63-68
[5]  
CHUMAKOV IM, 1995, NATURE, V377, P175
[6]  
Fenaux P, 1996, SEMIN HEMATOL, V33, P127
[7]   Myelodysplastic syndromes [J].
Fenaux, P .
HEMATOLOGY AND CELL THERAPY, 1996, 38 (05) :363-380
[8]  
FENAUX P, 1991, BLOOD, V78, P1652
[9]   The 17p-syndrome: A distinct myelodysplastic syndrome entity? [J].
Jary, L ;
Mossafa, H ;
Fourcade, C ;
Genet, P ;
Pulik, M ;
Flandrin, G .
LEUKEMIA & LYMPHOMA, 1997, 25 (1-2) :163-&
[10]  
JONVEAUX P, 1991, ONCOGENE, V6, P2243